 |
 |
|
|
|
| Glucagon Acetate |
 |
| C153H225N43O49S |
 |
| 16941-32-5 |
 |
| It is clinically used for the serious hypoglycemia reaction of diabetics under the treatment of insulin, the inhibition of gastrointestinal motility during gastrointestinal examination and the evaluation of maximum secretion of insulin β cell of diabetics. |
 |
Parameters of Product:
1 .Appearance :White powder
2 .Specific Optical Rotation (c=1,H2O) :-50.0~-60.0°
3 .Water Content(Karl Fischer) :≤10.0%
4 .Acetate Content(by HPLC) :≤15.0%
5 .Amino Acid Composition :±10% of theoretical
6 .Purity (by HPLC) :≥98.0%
7 .Single Impurity(by HPLC) :≤1.0%
8 .Peptide Content(by %N) :≥80%
9 .Assay(By Anhydrous, Acetic Acid-free ) :95.0~105.0%
10 .Bacterial Endotoxins :≤5EU/mg
|
|
|
|
|
|
